Endothelial cell sprouting assay
HUVEC cells (6 × 10 4 cells/well in EBM) were plated onto a thin layer (250 µL) of basement membrane matrix (Matrigel; BD Biosciences, Becton Dickinson, Waltham, MA, USA) in 24-well plates and co-cultured with WT or mPGES-1 +/+ tumor cells treated with 10% FBS medium, or mPGES-1 -/-tumor cells with or without PGE-2 (1 μM) in 10% FBS, or DU145 mPGES-1 -/-cells transfected with scramble or Dicer siRNA, or mPGES-1 -/-cells transfected with miRNA inhibitors, or mPGES-1 +/+ cells transfected with miRNA mimics. Co-cultures were incubated at 37°C in 5% CO 2 . After 12 h, the medium was removed and the cells were fixed and stained using DY554 phalloidin (Thermo Fisher Scientific, Waltham, MA, USA) for Factin. Images (magnification 4X) were obtained with a Nikon Eclipse TE 300 inverted microscope (4X/0.13). Quantification of cordlike structures and photomicrographs were performed as previously described [2] .
In vivo tumor xenograft study
Experiments observed EEC guidelines (Law No. 86/609) and National Ethical Committee rules. DU145 (20 6 ) and PC3 (10 6 ) cells were injected s.c. into the flank of 5-week-old male athymic nude mice. Tumor size was determined by measuring tumor length and width and calculating tumor weight (mg) [tumor length × (tumor width)2]/2, where tumor length is the longest dimension (mm) and tumor width is the shortest dimension (mm). Where indicated, at 1 week after tumor cell implant, mice were injected subcutaneously with mimic miR186 (3 µg/mouse) or negative control miRNA with in vivo jetPEI as vehicle (Polyplus transfection, Bioparc, Illkirch, France). Treatment was repeated three times/week for a total of 8 injections. No side effects such as changes in mouse body weight, behavioural changes or other signs of discomfort were observed. 48 h after the last treatment, mice were sacrificed (by CO 2 asphyxiation 19 days after the first treatment and/or tumor volume measurement). Tumors were harvested and used to analyse protein [3], mRNA and miRNA expression or embedded in Tissue-Tek O.C.T. (Sakura, San Marcos, CA, USA) for histological examination. Tumor volume was expressed in mm3. Efficient delivery of miR-186 mimic was confirmed by qPCR (expression of mature miR-186 increased by a factor of ~4.3 in miR-186-treated with respect to control treated mice; P < 0.001). Cryostat sections (6 µm thick) of tissue samples were processed for immunohistochemical staining.
Immunohistochemistry
For histopathological analysis of CD31 we used hematoxylin and immunohistochemical staining. First, sections were fixed with acetone at -20°C for 5 min. After inactivating of endogenous peroxidase activity and blocking cross-reactivity with 3% BSA, the sections were incubated at 37°C for 1 h with dilute CD31 solution (1:100, Chemicon, Merck-Millipore, Darmstadt, Germania). Primary antibodies were located by subsequent application of biotin-conjugated antiprimary antibody, streptavidinperoxidase and diaminobenzidine (Sigma Aldrich, Saint Louis, MO, USA). The stain was developed using a commercial immunoperoxidase staining kit according to the manufacturer's instructions (biotin-streptavidin complex method, Merck-Millipore). The slides were counter-stained with hematoxylin. Negative controls were established by replacing the primary antibody with PBS. Specific staining for CD31 was scored as positive or negative according to the presence or absence of brown staining. Images were analyzed using a Nikon Eclypse T200 at magnification 20X/0.40.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay (ChIP) assays were performed as previously described [4] . In Brief DU145 cells (3 × 10 6 ) were maintained in RPMI with 10% FBS for 24 h and stimulated with PGE-2 for the indicated times. Cells were then fixed with 1% formaldehyde for 5 min at 37°C and lysed in ice-cold lysis buffer (10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, 0.1% NP-40 and protease inhibitors) for 10 min at 4°C. The nuclei pellet was suspended in nuclear lysis buffer (50 mM Tris-HCl pH 8, 10 mM EDTA, 1% SDS and protease inhibitors) and incubated on ice for 10 min. DNA was sheared by sonication and lysates were cleared by centrifuging and diluted in ChIP dilution buffer (50 mM Tris-HCl pH 8, EDTA 5 mM, NaCl 200 mM, and 0.5% NonidetP-40). Lysates were precleared with salmon sperm/protein A-agarose. A sample of "input DNA" was collected at this point. Protein-DNA complexes were immunoprecipitated overnight at 4°C with 2 μg of the corresponding antibody or non-immune rabbit serum as a control. Antibody-protein-DNA complexes were then captured using salmon sperm DNA/protein agarose for 30 min followed by washes with wash buffer (20 mM TrisHCl pH 8, 2 mM EDTA, 0.1% SDS, 1% NP-40 and 500 mM NaCl) and TE buffer (20 mM Tris-HCl and 2 mM EDTA). The protein/DNA complexes were eluted using extraction buffer (20 mM Tris-HCl, 2 mM EDTA and 2% SDS) and disrupted by heating at 65°C overnight followed by proteinase K treatment for 2 h at 45°C. DNA was extracted with a Purification kit (Sigma Aldrich). QPCR was conducted using promoter specific primers from Qiagen (20 mM Tris-HCl pH 8, 2 mM EDTA, 0.1% SDS, 1% NP-40 and 500 mM NaCl) and TE buffer (20 mM Tris-HCl and 2 mM EDTA). The protein/DNA complexes were eluted using extraction buffer (20 mM Tris-HCl, 2 mM EDTA and 2% SDS) and disrupted by heating at 65°C overnight followed by proteinase K treatment for 2 h at 45°C. DNA was extracted with a Purification kit (Sigma Aldrich). QPCR was conducted using promoter specific primers from Qiagen (GPH1018139(+)05A, in position 4930).
Statistical analysis
Results are expressed as means ± SD. Statistical analysis was performed using ANOVA followed by Bonferroni test and Student t test when appropriate (GraphPad). P<0.05 was considered statistically significant. 
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